Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation –
SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...

Related Keywords

California ,United States ,Northwestern University ,Illinois ,Rochester ,New York ,Portland ,Oregon ,Alabama ,Germany ,Canada ,Sugarloaf ,San Francisco ,Bonn ,Nordrhein Westfalen ,Washington ,Chicago ,Berlin ,Thomas Bieber ,Jonathan Zalevsky ,David Rosmarin ,Andrew Blauvelt ,Mary Tagliaferri ,Zachary Lee ,Brian Kotzin ,Eli Lilly ,Vivian Wu ,Sohail Chaudhry ,Sstephen Schleicher ,Danni Yu ,Mario Marcondes ,Raj Chovatiya ,David Rosen ,Alisa Beck ,Timothy Rodgers ,Jonathan Silverberg ,Yi Liu ,Carsten Schmitz ,Melinda Gooderham ,Christie Fanton ,Ajay Nirula ,Nektar Therapeutics ,Research Development ,Exchange Commission On ,Indiana University School Of Medicine ,Oregon Medical Research Center ,Icans School Of Medicine At Mt ,European Academy Of Dermatology ,Queen University ,Skin Sciences ,Department Of Medicine ,Rochester Medical Center ,Dermdox Centers For Dermatology ,Feinberg School ,George Washington University School ,Allergy Research And Education ,Efficacy Data ,Severe Atopic Dermatitis ,Late Breaking Oral Presentation ,Senior Vice President ,Chief Research ,Development Officer ,Single Agent Rezpegaldesleukin ,Selective Regulatoryt Cell Inducing ,Atopic Dermatitis ,Final Results ,Randomized Phase ,Late Breaking ,George Washington University School Of Medicine ,University School ,School Of Medicine ,Dox Centers ,Placebo Controlled Study ,Moderate To Severe Atopic Dermatitis ,Medical Research Center ,Center For Allergy Research And Education ,University Of Bonn ,Annual Report ,Exchange Commission ,Markets ,